Shire Licenses Rights to Duchenne Muscular Dystrophy Drug Candidate from Acceleron
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 8 (Table of Contents)
Published: 18 Oct-2010
DOI: 10.3833/pdr.v2010.i8.1389 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Shire has entered into a joint development and commercialisation agreement worth US$498 M with Acceleron Pharma to develop drugs to treat rare muscle disorders, including Duchenne muscular dystrophy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS